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 BACKGROUND:  Skeletal muscle impairment is a recognized complication of COPD, predicting 
mortality in severe disease. Increasing evidence implicates the renin-angiotensin system in 
control of muscle phenotype. We hypothesized that angiotensin-converting enzyme (ACE) 
inhibition would improve quadriceps function and exercise performance in COPD. 
 METHODS:  Th is double-blind, randomized placebo-controlled trial investigated the eff ect of 
the ACE inhibitor, fosinopril, on quadriceps function in patients with COPD with quadriceps 
weakness. Primary outcomes were change in quadriceps endurance and atrophy signaling at 
3 months. Quadriceps maximum voluntary contraction (QMVC), mid-thigh CT scan of the 
cross-sectional area (MTCSA), and incremental shuttle walk distance (ISWD) were secondary 
outcomes. 
 RESULTS:  Eighty patients were enrolled (mean [SD], 65 [8] years, FEV 1 43% [21%] predicted, 
53% men). Sixty-seven patients (31 fosinopril, 36 placebo) completed the trial. Th e treatment 
group demonstrated a signifi cant reduction in systolic BP (  2 10.5 mm Hg; 95% CI,  2 19.9 to 
 2 1.1;  P  5 .03) and serum ACE activity (  2 20.4 IU/L; 95% CI,  2 31.0 to  2 9.8;  P  , .001) com-
pared with placebo. No signifi cant between-group diff erences were observed in the primary 
end points of quadriceps endurance half-time (  0.5 s; 95% CI,  2 13.3-14.3;  P  5 .94) or atrogin-1 
messenger RNA expression (  2 0.03 arbitrary units; 95% CI,  2 0.32-0.26;  P  5 .84). QMVC 
improved in both groups (fosinopril:   1.1 kg; 95% CI, 0.03-2.2;  P  5 .045 vs placebo:   3.6 kg; 
95% CI, 2.1-5.0;  P  , .0001) with a greater increase in the placebo arm (between-group,  P  5 .009). 
No change was shown in the MTCSA ( P  5 .09) or ISWD ( P  5 .51). 
 CONCLUSIONS:  Th is randomized controlled trial found that ACE inhibition, using fosinopril 
for 3 months, did not improve quadriceps function or exercise performance in patients with 
COPD with quadriceps weakness. 
 TRIAL REGISTRY:  Current Controlled Trials; No.: ISRCTN05581879; URL: www.controlled-
trials.com  CHEST 2014; 146(4): 932 - 940 
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2014; originally published Online First   February 20, 2014. 
 ABBREVIATIONS:  ACE  5 angiotensin-converting enzyme; AU  5 arbitrary 
unit; CAT  5 COPD assessment test; IGF  5 insulin-like growth factor; 
ISWD  5 incremental shuttle walk distance; mRNA  5 messenger RNA; 
MTCSA  5 mid-thigh CT scan of the cross-sectional area; QMVC  5 
quadriceps maximum voluntary contraction; SGRQ  5 St. George’s 
Respiratory Questionnaire; TwQ  5 quadriceps twitch force 
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 Skeletal muscle impairment is a key extrapulmonary 
complication of COPD, aff ecting approximately one-
third of patients independent of the degree of airfl ow 
obstruction. 1,2 In particular, quadriceps weakness in 
COPD has been associated with reduced exercise 
capacity, 3 impaired quality of life, 4 and mortality in 
patients with moderate to severe disease. 5 Importantly, 
pulmonary rehabilitation, which improves exercise 
performance and reduces health-care utilization, also 
increases quadriceps strength. 6,7 
 Th e mechanisms responsible for skeletal muscle dys-
function in COPD remain a matter of controversy and 
are likely multifactorial, but there is evidence that 
chronic activation of the IM renin-angiotensin system 
may be a key pathophysiologic pathway. 8 In animal 
models, 9-11 angiotensin II promotes muscle loss via an 
inhibitory eff ect on the insulin-like growth factor 
(IGF)-1 system and stimulation of a catabolic pathway 
mediated by two ubiquitin ligases, the atrogenes: muscle 
RING fi nger protein-1 and atrogin-1. Th rough ubiquitin-
proteasome degradation, these ligases have been postu-
lated to play a key role in the muscle atrophy observed 
in patients with COPD. 12 
 In addition, an endogenous reduction in serum and 
tissue angiotensin-converting enzyme (ACE) levels as a 
result of polymorphism of the human ACE gene has 
been associated with an enhanced endurance phenotype 13 
with the presence of a deletion allele (D) shown to corre-
late with greater quadriceps strength in COPD. 14 A poly-
morphism determining a reduction in bradykinin 
 Materials and Methods 
 Participants 
 Th e study was approved by the Joint University College London 
Committees on the Ethics of Human Research (reference number 
08/H0715/90), and each participant gave informed written consent. 
Study inclusion criteria were patients diagnosed with COPD based on 
GOLD (Global Initiative for Chronic Obstructive Lung Disease) cri-
teria 23 and the presence of quadriceps weakness defi ned as a quadriceps 
maximum voluntary contraction (QMVC) in kilograms  , 120% of the 
patient’s BMI. 5 Exclusion criteria were patients within 3 months of pul-
monary rehabilitation or 1 month of an exacerbation, and those with a 
comorbidity including cardiac failure, diabetes, renal disease, or rheu-
matoid arthritis. Patients receiving ACE inhibitors, angiotensin II receptor 
blockers, or warfarin (because the study entailed a vastus lateralis 
biopsy) were also excluded. 
 Study Design 
 Th e study was a double-blind, randomized, placebo-controlled, parallel-
group trial. Patients were randomly allocated to either ACE inhibitor 
(fosinopril 10 mg, once a day) or placebo (lactose) for a 3-month period. 
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receptor expression has also been associated with a 
reduced fat-free mass and quadriceps strength in 
patients with COPD. 15 
 Further evidence has come from observational studies 
in hypertensive cohorts where treatment with an ACE 
inhibitor has been associated with increased locomotor 
muscle size 16 and strength. 17 Th is is supported by ran-
domized controlled trials where ACE inhibition has 
FOR EDITORIAL COMMENT SEE PAGE  878 
increased 6-min walking distance in elderly subjects 18 
and angiotensin II receptor blockade has shown a trend 
toward an improvement in quadriceps strength in sub-
jects with COPD. 19 
 Given this evidence base and the increasing focus 
toward the development of pharmacotherapy targeting 
skeletal muscle, 20,21 we hypothesized that ACE inhibition 
would have a benefi cial eff ect on quadriceps function in 
patients with COPD. To strengthen the design of the 
trial we used a stratifi ed medicine approach, selecting 
patients with quadriceps weakness using the cutoff  that 
has been found to be associated with increased mortality 
in COPD. 5 Quadriceps endurance, measured by repeti-
tive magnetic stimulation, was used as the primary out-
come due to the asso ciation of reduced ACE levels with 
greater endurance in healthy subjects 13 and the advan-
tages of a nonvolitional test in the context of a population 
with severe airfl ow limitation. 22 
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Resting BP and renal function were reviewed at 1 week by an indepen-
dent assessor and if satisfactory, the daily dose was increased to two 
capsules (fosinopril 20 mg maximum or placebo). Dose was not escalated 
if the systolic BP was  , 110 mm Hg. A pharmacy controlled, 1:1 ran-
domization in blocks of four using consecutive numbers was performed 
by the Clinical Trials Department, Royal Free Hampstead NHS Trust 
UK. Primary outcomes were change in quadriceps endurance measured 
nonvolitionally by repetitive magnetic stimulation 22 and vastus late-
ralis atrophy signaling using atrogene expression from biopsies taken 
at baseline and 3 months. Secondary outcomes included change in 
QMVC, quadriceps twitch force (TwQ), mid-thigh CT scan of the cross-
sectional area (MTCSA), incremental shuttle walk distance (ISWD), 
health status, and serum infl ammatory markers. Measurements of fat-
free mass, BP, lung function, and anthropometrics were also made and 
a single assessment of baseline physical activity was conducted using 
a multisensor armband worn for 1 week as previously described. 2 
Further details of the trial protocol and methods are available online 
( e-Appendix 1 ,  e-Tables 1, 2 ). 
 Analysis and Statistics 
 Detecting a 25% increase in time to fatigue in the fosinopril vs placebo 
groups, with an 80% power at the 5% signifi cance level, would require 
54 patients randomized on a 1:1 basis. To allow for a 30% dropout rate, 
80 patients were targeted for recruitment. Data were normally distrib-
uted and a per-protocol analysis was conducted using paired or inde-
pendent  t tests. Response variables were tested by analysis of variance 
with post hoc correction for more than two groups. Multiple linear regres-
sion analysis was performed to identify baseline parameters infl uenc-
ing response to treatment. Analysis was performed using StatView 5.0 
(Abacus Concepts) with  P  , .05 considered statistically signifi cant. 
 Results 
 One hundred seventeen patients were screened for 
study participation, and 80 patients underwent 
randomization. Th ere were eight withdrawals from 
the treatment group and five from the placebo 
group. Further details are shown in the CONSORT 
diagram ( Fig 1 ). 
 Baseline Anthropometrics and Muscle 
Measurements 
 Th e placebo and treatment groups were well matched 
for age, sex, and lung function parameters and there 
were no statistically signifi cant baseline diff erences in 
body composition and quadriceps muscle function 
( Table 1 ). Th ere were also no signifi cant baseline diff er-
ences in vastus lateralis atrogene expression and serum 
measurements between the groups ( e-Table 3 ). 
 Physiologic Outcomes Following ACE Inhibition 
 Quadriceps Function:  At 3 months, there was no sig-
nifi cant diff erence in quadriceps endurance assessed by 
repetitive magnetic stimulation (fosinopril:   5.1 s; 95% CI, 
 2 4.3-14.5;  P  5 .27 vs placebo:   4.6 s; 95% CI,  2 5.8-15.1; 
 P  5 .37 [between-group diff erence, 0.5 s; 95% CI, 
 2 13.3-14.3;  P  5 .94]) ( Fig 2A ). QMVC improved in 
both groups (fosinopril:   1.1 kg; 95% CI, 0.03-2.2; 
 P  5 .045 vs placebo:   3.6 kg; 95% CI, 2.1-5.0;  P  , .0001) 
with a greater increase in the placebo arm (between-
group diff erence, 2.5 kg; 95% CI, 0.7-4.3;  P  5 .009) ( Fig 2B ). 
TwQ response did not diff er in the placebo vs treatment 
  
 Figure 1 –  CONSORT diagram for enrolment and follow-up. CA  5 carcinoma; CVA  5 cerebrovascular accident; QMVC  5 quadriceps maximum 
voluntary contraction. 
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 TABLE 1  ]  Demographic and Baseline Clinical Characteristics of Placebo and Treatment Groups 
Clinical Characteristics
Group, Mean (SD)
 P ValuePlacebo (n  5 41) Treatment (n  5 39)
Age, y 64.6 (7.3) 66.3 (8.2) .33
Sex, male (female) 23 (18) 19 (20) .51
BMI, kg/m 2 24.3 (4.0) 25.0 (5.8) .51
FFMI, kg/m 2 17.0 (2.1) 17.3 (2.6) .60
Smoking, pack-y 53.3 (25.1) 49.8 (33.1) .59
Current smokers, % 24 28 .70
Long-acting  b agonist, % 93 82 .15
Long-acting anticholinergic, % 88 87 .93
Inhaled corticosteroid, % 90 82 .15
Oral corticosteroid,   5 mg/d, % 2 5 .53
FEV 1  % predicted 40.1 (20.6) 45.8 (20.5) .22
D L co % predicted 41.8 (20.9) 44.0 (19.2) .64
RV to TLC ratio, % 58.2 (9.9) 55.8 (10.7) .29
Pa O 2 , kPa 9.7 (1.4) 9.6 (1.4) .82
Pa CO 2 , kPa 5.2 (0.6) 5.1 (0.4) .18
SGRQ, symptoms 56.5 (23.7) 49.6 (21.3) .17
SGRQ, activity 70.8 (25.8) 71.1 (17.2) .96
SGRQ, impacts 40.8 (22.8) 31.3 (16.2) .04
SGRQ, total 52.5 (22.0) 46.4 (14.9) .15
CAT score 22.8 (8.5) 20.8 (8.1) .34
Daily step count 4499 (3462) 4504 (3109) .99
PAL 1.4 (0.18) 1.4 (0.16) .66
Systolic BP, mm Hg 134 (15) 138 (19) .35
Diastolic BP, mm Hg 85 (10) 85 (11) .84
 b -Blocker, % 2 0 .33
Calcium channel blocker, % 7 10 .65
Diuretic, % 0 2 .31
Serum NT-proBNP, ng/L 109.0 (99.8) 105.0 (64.0) .85
ACE genotype: DD, ID, II, % 39,44,17 38,46,16 .94
QMVC, kg 24.9 (4.9) 25.0 (7.4) .98
TwQ, kg 10.7 (3.0) 9.7 (3.4) .21
MTCSA, cm 2 93.3 (22.4) 93.0 (26.1) .96
Endurance half-time, s 61.2 (35.5) 70.6 (31.9) .30
ISWD, m 247 (132) 242 (128) .87
 ACE  5 angiotensin-converting enzyme; CAT  5 COPD assessment test; D LCO  5 diﬀ using capacity of the lung for carbon monoxide; FFMI  5 fat free mass 
index; ISWD  5 incremental shuttle walk distance; MTCSA  5 mid-thigh CT scan of the cross-sectional area; NT-proBNP  5 N-terminal pro-B-type 
natriuretic peptide; PAL  5 physical activity level; QMVC  5 quadriceps maximum voluntary contraction; RV  5 residual volume; SGRQ  5 St. George’s 
Respiratory Questionnaire; TLC  5 total lung capacity; TwQ  5 quadriceps twitch force. 
group (fosinopril:   2 0.28 kg; 95% CI,  2 1.0-0.45; 
 P  5 .43 vs placebo:   0.57 kg; 95% CI, 0.01-1.1;  P  5 .046 
[between-group diff erence, 0.85 kg; 95% CI,  2 1.7-0.03; 
 P  5 .06]). MTCSA also showed no signifi cant diff er-
ences at 3 months (fosinopril:   2 0.60 cm 2 ; 95% CI, 
 2 2.1-0.91;  P  5 .42 vs placebo:   1.0 cm 2 ; 95% CI, 
 2 0.21-2.2;  P  5 .10 [between-group diff erence,  2 1.6 cm 2 ; 
95% CI,  2 3.5-0.27;  P  5 .09]). 
 Exercise Capacity, BP, and Lung Function:  Th ere was 
no signifi cant change in ISWD at 3 months in the two 
groups (fosinopril:   7.1 m; 95% CI,  2 5.5-19.7;  P  5 .26 
vs placebo:   17.1 m; 95% CI,  2 10.6-44.8;  P  5 .22 
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[between-group diff erence,  2 10 m; 95% CI,  2 39.8-19.8; 
 P  5 .51]). A signifi cant reduction was demonstrated in 
systolic BP in the treatment arm compared with placebo 
(fosinopril:   2 12.7 mm Hg; 95% CI,  2 20.3 to  2 5.1; 
 P  5 .002 vs placebo:   2 2.2 mm Hg; 95% CI,  2 8.1-3.7; 
 P  5 .46 [between-group diff erence,  2 10.5 mm Hg; 95% CI, 
 2 19.9 to  2 1.1;  P  5 .03]) ( Fig 2C ). Diastolic BP was 
also reduced in the treatment group (fosinopril: 
  2 7.0 mm Hg; 95% CI,  2 11.5 to  2 2.4;  P  5 .004 vs placebo: 
  2 1.2 mm Hg; 95% CI,  2 5.2-2.9;  P  5 .56 [between-group 
diff erence,  2 5.8 mm Hg; 95% CI,  2 11.7-0.11;  P  5 .05]). 
Lung function parameters including FEV 1 % predicted, 
diff using capacity of the lung for carbon monoxide % 
predicted, residual volume-to-total lung capacity ratio, 
and arterial blood gas measurements showed no signifi -
cant change between groups at 3 months, as shown in 
 Table 2 . Health-related quality-of-life measures, which 
included St. George’s Respiratory Questionnaire (SGRQ) 
and COPD assessment test (CAT) score, also did not 
vary signifi cantly between groups ( Table 2 ). 
 Molecular Outcomes Following ACE Inhibition 
 Vastus Lateralis messenger RNA Expression:  At 
3 months, no signifi cant diff erences were observed in 
vastus lateralis atrogin-1 messenger RNA (mRNA) 
 Figure 2 – A, Quadriceps endurance following 3 mo ACE inhibition vs placebo (data shown as mean with cross bars representing the SEM). 
 B, QMVC following 3 mo ACE inhibition vs placebo (data shown as mean with cross bars representing SEM). C, Systolic BP following 3 mo ACE inhibi-
tion vs placebo (data shown as mean with cross bars representing SEM). D, Serum ACE activity following 3 mo ACE inhibition vs placebo (data shown 
as mean with cross bars representing SEM). ACE  5 angiotensin-converting enzyme; NS  5 not signifi cant. See  Figure 1 legend for expansion of other 
abbreviations. 
expression (fosinopril:   2 0.18 arbitrary units [AU]; 
95% CI,  2 0.41-0.04;  P  5 .11 vs placebo:   2 0.15 AU; 
95% CI,  2 0.35-0.04;  P  5 .12 [between-group diff erence, 
 2 0.03 AU; 95% CI,  2 0.32-0.26;  P  5 .84]) or muscle 
RING fi nger protein-1 mRNA expression (fosinopril: 
  0.09 AU; 95% CI,  2 0.21-0.39,  P  5 .55 vs placebo: 
  2 0.13 AU; 95% CI,  2 0.32-0.05;  P  5 .14 [between-group 
diff erence, 0.22 AU; 95% CI,  2 0.11-0.55;  P  5 .18]). 
Vastus lateralis IGF-1 mRNA expression also showed no 
signifi cant diff erence between groups (0.04 AU; 95% CI, 
 2 0.38-0.46;  P  5 .84) at 3 months. Further data showing 
no signifi cant diff erence in vastus lateralis transforming 
growth factor- b , MyoD, MHC I, IIA, and IIX mRNA 
expression and protein levels of phosphorylated 4EBP-1 
are shown in the online supplement ( e-Table 4 ). 
 Serum Measurements:  Th e treatment group demon-
strated a signifi cant reduction in serum ACE activity 
compared with placebo (fosinopril:   2 17.4 IU/L; 95% CI, 
 2 28.1 to  2 6.8;  P  5 .002 vs placebo:   3.0 IU/L; 95% CI, 
 2 1.2-7.1;  P  5 .15 [between-group diff erence,  2 20.4 IU/L; 
95% CI,  2 31.0 to  2 9.8;  P  5 .0003) ( Fig 2D ). No signifi cant 
diff erences were found in serum IGF-1, high-sensitivity 
C-reactive protein, N-terminal pro-B-type natriuretic 
peptide, fi brinogen, or serum infl ammatory cytokines 
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between the groups as shown in  e-Table 4 . A post hoc 
stratifi cation based on ACE genotype did not infl uence 
response to treatment as detailed online ( e-Tables 5, 6 ). 
Multiple linear regression analysis did not identify any 
baseline demographic, anthropometric, lung function, 
or physical activity variables infl uencing response to 
treatment. Data on dropouts from the study are shown 
in  e-Table 7 . 
 Discussion 
 ACE inhibition by fosinopril did not have a benefi cial 
eff ect on quadriceps muscle function over a 3-month 
period in patients with COPD selected for quadriceps 
weakness, although measurements of BP and serum 
ACE activity confi rmed both adherence and biologic 
activity of the drug. Moreover, we were unable to detect 
any changes in atrophy signaling pathways in the partic-
ipants. Th e present data do not support the use of ACE 
inhibitors alone to augment muscle phenotype in 
patients with COPD. 
 Th ese fi ndings were unexpected given the evidence for 
ACE inhibition on skeletal muscle function, and reinforce 
the importance of conducting prospective controlled 
trials. An observational study by Onder et al 17 assessed 
the relationship between ACE inhibitor use and muscle 
strength in 641 elderly hypertensive women. Th ey found 
that at 3 years’ follow-up, participants taking an ACE 
inhibitor continuously had a lower mean decline in both 
knee extensor muscle strength and walking speed than 
those using other antihypertensives and those not on 
any antihypertensive medications. Intermittent use of 
ACE inhibitors was also associated with a signifi cantly 
larger decline in walking speed compared with contin-
uous use. Th e study group had poor mobility but no 
concomitant heart failure at baseline. In addition, cross-
sectional data from 2,431 hypertensive subjects was used 
to evaluate whether ACE inhibitor treatment is associ-
ated with a larger lower extremity muscle mass compared 
with the use of other antihypertensive medications, 16 
and found that lower extremity muscle mass was larger 
in the ACE inhibitor group in a manner proportional to 
the length of use. 
 Interventional studies of ACE inhibition have also sug-
gested a treatment eff ect. A randomized controlled trial 
in 95 elderly subjects with self-reported diffi  culties in 
mobility, showed that 5 months of perindopril treatment 
signifi cantly improved 6-min walk distance (31.4 m; 
95% CI, 10.8 m-51.9 m;  P  5 .003) compared with placebo. 18 
Interestingly, this cohort included current and ex-smokers 
and the improvement was observed in the absence of 
heart failure in the participants. In addition, a small ran-
domized controlled trial of 21 subjects with COPD eval-
uating the eff ects of 4 weeks’ treatment with enalapril on 
exercise performance found a signifi cant improvement 
in O 2 pulse and peak work rate in the treatment group. 24 
 Th ere are a number of possible factors that may explain 
why ACE inhibition was not eff ective in the present 
 TABLE 2  ]  Physiologic and HRQOL Measurements Before and After 3 Mo of ACE Inhibition 
Measurements
Placebo Group, mean (SEM) (n  5 36) Treatment Group, mean (SEM) (n  5 31) Change Between 
Groups  P ValueBaseline 3 Mo Baseline 3 Mo
TwQ, kg a 10.7 (0.5) 11.3 (0.6) 10.1 (0.8) 9.8 (0.8) .06
MTCSA, cm 2 94.1 (3.7) 95.1 (3.6) 94.5 (4.9) 93.9 (4.9) .09
ISWD, m 247.4 (23.8) 264.5 (29.2) 241.9 (23.0) 249.0 (23.3) .51
Diastolic BP, mm Hg 84.8 (1.6) 83.6 (1.8) 85.9 (2.1) 78.9 (2.3) .05
FEV 1 % predicted 40.0 (3.5) 42.7 (3.7) 44.8 (3.6) 46.1 (3.9) .50
D LCO % predicted 43.3 (3.7) 44.5 (3.9) 44.5 (3.7) 44.2 (3.7) .20
RV to TLC ratio, % 58.4 (1.7) 56.3 (1.8) 56.2 (1.9) 55.0 (2.0) .35
Pa O 2 , kPa 9.6 (0.2) 9.5 (0.3) 9.6 (0.3) 9.6 (0.3) .77
Pa CO 2 , kPa 5.3 (0.1) 5.3 (0.1) 5.1 (0.1) 5.1 (0.1) .79
SGRQ, symptoms 55.4 (4.0) 53.6 (4.3) 50.3 (3.7) 54.3 (4.0) .25
SGRQ, activity 70.3 (4.4) 68.8 (4.1) 72.0 (3.1) 70.5 (4.1) .99
SGRQ, impacts 40.2 (3.8) 39.6 (3.7) 32.2 (2.8) 34.5 (3.4) .28
SGRQ, total 51.9 (3.7) 50.8 (3.6) 47.3 (2.6) 48.8 (3.1) .25
CAT score 22.2 (1.5) 19.7 (1.6) 21.0 (1.6) 20.7 (1.5) .18
 HRQOL  5 health-related quality of life. See  Table 1 legend for expansion of other abbreviations. 
 a TwQ: placebo (n  5 32), treatment (n  5 25) due to below supramaximal twitch response. 
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study given previous data. Th ese are discussed here and 
include the patient population studied, the infl uence of 
physical inactivity, and the possibility that ACE inhibi-
tion created a more “benign” IM environment, eff ec-
tively removing a training stimulus. 
 Patient Selection 
 We adopted a stratifi ed medicine approach, selecting a 
quadriceps weakness patient phenotype, to focus on 
those patients with COPD with a level of skeletal muscle 
dysfunction known to be associated with worse sur-
vival. 5 It may, however, be that at this stage the weakest 
patients have a limited ability to respond to treatment 
and the low physical activity level found at baseline may 
refl ect this. Th e level of inactivity could explain the dis-
crepancy between the present data and the eff ect of ACE 
inhibitors in relatively healthy populations being treated 
for hypertension. 17 Th ere is also evidence that an exer-
cise stimulus may be needed for ACE inhibition to pro-
mote adaptive changes, such as an increase in capillary 
density, in skeletal muscle. 25 Th erefore, the current data 
do not preclude the possibility that the use of ACE inhi-
bition in the context of pulmonary rehabilitation may 
yield benefi t. 
 Skeletal muscle impairment in COPD involves both 
fi ber atrophy and fi ber shift  away from an oxidative, 
fatigue-resistant phenotype. 26 In any individual, these 
processes occur to a varying extent with diff erent eff ects 
on muscle function. The D allele of the ACE (I/D) 
polymorphism, which is associated with higher ACE 
activity, was associated with greater quadriceps 
strength in patients with COPD. 14 Th e eff ects of ACE 
inhibition may therefore counteract strength adapta-
tions seen in COPD, in favor of achieving a more 
aerobic phenotype. Th is trial was not prospectively 
powered for stratifi cation by ACE genotype, so although 
post hoc analysis did not identify a genotype-specifi c 
infl uence on quadriceps function, this method of strat-
ifi cation would be an important consideration for 
future studies. 
 Eﬀ ect of ACE Inhibition on IM Environment 
 Th e improvements observed in quadriceps strength in 
the current trial warrant further discussion. As subjects 
were included based on the presence of quadriceps 
weakness, it is not completely unexpected that a poten-
tial placebo eff ect with regression to the mean would be 
observed in relation to volitional quadriceps strength, 
although more detailed monitoring of physical activity 
throughout the trial period would be needed to support 
this. Th e existence of a placebo eff ect has been well doc-
umented in the context of functional exercise capacity 
in clinical trials of ACE inhibition in heart failure 27 and 
in other studies of physical performance. 28 However, the 
fi nding that this eff ect was greater in the placebo arm of 
the trial was unexpected. While this could be a chance 
eff ect, this seems unlikely because of the high level of 
statistical signifi cance shown ( P  5 .009). A possible 
reduction in skeletal muscle blood fl ow secondary to a 
reduced systemic BP may explain the attenuated response 
observed with treatment. Of note, captopril has been 
shown to increase maximal blood lactate during exer-
cise and reduce exercise capacity in normotensive, 
sedentary rats. 29 
 Despite evidence from animal models of the ability to 
prevent angiotensin II-induced cachexia via IGF-1 
overexpression and atrogene downregulation, 10 ACE 
inhibition was not shown to have a translational ben-
efit in patients with COPD. This demonstrates that, 
at least over a 3-month period, fosinopril does not 
alter atrophy signaling at a tissue level, despite a 
clear systemic effect on BP and serum ACE activity. 
Importantly, there is evidence to suggest this systemic 
effect would have inhibited tissue ACE. 30 However, 
local tissue renin-angiotensin system can generate 
angiotensin II, independent of ACE activity, through 
serine proteases such as chymase and cathepsin G 31 
and this may explain the lack of influence of ACE 
inhibition on skeletal muscle. The timing of biopsies 
may have also influenced the ability to detect changes 
following ACE inhibition and, therefore, early biopsies, 
where feasible, may guide further mechanistic work 
in this area. 
 Critique of the Method 
 A strength of this study was that the quadriceps assess-
ment was comprehensive including both volitional and 
nonvolitional physiologic outcomes as well as molecular 
outcomes. Although no signifi cant changes were shown 
in the activity domain of the SGRQ, the infl uence of 
treatment on physical activity level was not objectively 
assessed in this trial. Th e baseline inclusion of physical 
activity monitoring did, however, objectively confi rm 
that both groups were well matched for their level of 
physical activity when commencing the trial. Impor-
tantly, this activity level was in keeping with published 
data on patients from other northern European coun-
tries, 32 highlighting the overall generalizability of the 
study population findings. However, the inclusion 
of more patients with varying degrees of muscle 
impairment may have enabled a wider assessment of 
potential responders. 
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